Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 2288 | 0.675 |
09:39 ET | 7449 | 0.6914 |
09:41 ET | 2500 | 0.6914 |
09:43 ET | 187 | 0.6857 |
09:48 ET | 100 | 0.6883 |
09:50 ET | 100 | 0.692 |
09:56 ET | 200 | 0.692 |
10:03 ET | 100 | 0.6848 |
10:06 ET | 200 | 0.6873 |
10:10 ET | 700 | 0.6873 |
10:12 ET | 3098 | 0.69 |
10:14 ET | 155 | 0.68 |
10:24 ET | 1500 | 0.6815 |
10:33 ET | 530 | 0.6889 |
11:11 ET | 100 | 0.6869 |
11:13 ET | 200 | 0.68 |
11:42 ET | 342 | 0.675 |
11:45 ET | 100 | 0.675 |
11:51 ET | 122 | 0.677501 |
11:56 ET | 1100 | 0.675 |
12:14 ET | 100 | 0.669 |
12:23 ET | 498 | 0.6784 |
12:30 ET | 100 | 0.669 |
12:43 ET | 300 | 0.6799 |
12:52 ET | 100 | 0.671 |
12:56 ET | 258 | 0.6798 |
12:57 ET | 129 | 0.6798 |
12:59 ET | 1100 | 0.6749 |
01:01 ET | 500 | 0.671 |
01:14 ET | 100 | 0.6797 |
02:02 ET | 100 | 0.6744 |
02:04 ET | 100 | 0.6798 |
02:15 ET | 1100 | 0.67223 |
02:20 ET | 100 | 0.669 |
02:22 ET | 100 | 0.6798 |
02:26 ET | 400 | 0.669001 |
02:29 ET | 232 | 0.67 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 24.4M | -1.9x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 4.6M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Bon Natural Life Ltd | 9.6M | 0.5x | +78.05% |
Qilian International Holding Group Ltd | 23.8M | -3.4x | --- |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.4M |
---|---|
Revenue (TTM) | $37.9M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-0.35 |
Book Value | $0.64 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.